Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Aktis Oncology, Inc. Chief Medical Officer Akos Czibere reported an exercise-and-sell transaction in Common Stock on July 8, 2026. He exercised stock options to acquire 50,000 shares at $4.95 per share, then sold 50,000 shares in multiple open-market sales at weighted average prices around the high-$20s range, leaving no Common Stock held directly and 221,218 stock options outstanding with a $4.95 exercise price expiring on June 30, 2034.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 50,000 shares ($1,388,701)
Net Sell
5 txns
Insider
Czibere Akos
Role
Chief Medical Officer
Sold
50,000 shs ($1.39M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 50,000 | $0.00 | -- |
| Exercise | Common Stock | 50,000 | $4.95 | $248K |
| Sale | Common Stock | 14,800 | $27.1273 | $401K |
| Sale | Common Stock | 30,829 | $27.9521 | $862K |
| Sale | Common Stock | 4,371 | $28.7078 | $125K |
Holdings After Transaction:
Stock Option (Right to Buy) — 221,218 shares (Direct, null);
Common Stock — 50,000 shares (Direct, null)
Footnotes (1)
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.5200 to $27.5100, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.5300 to $28.5000, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.6300 to $28.7400, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
Key Figures
Shares sold: 50,000 shares of Common Stock
Sale prices (weighted averages): $27.1273, $27.9521, $28.7078 per share
Option exercise price: $4.95 per share
+5 more
8 metrics
Shares sold
50,000 shares of Common Stock
Total open-market sales by Akos Czibere on July 8, 2026
Sale prices (weighted averages)
$27.1273, $27.9521, $28.7078 per share
Weighted average prices for three tranches of Common Stock sold
Option exercise price
$4.95 per share
Exercise price for 50,000 stock options converted into Common Stock
Options exercised
50,000 stock options
Number of options exercised by Akos Czibere on July 8, 2026
Options held after transaction
221,218 stock options
Total stock options remaining after the reported exercise
Option expiration date
June 30, 2034
Expiration for the stock option (right to buy) position
Common Stock held after transaction
0 shares
Direct Common Stock holdings of Akos Czibere following the sales
Sale price ranges
$26.5200–$28.7400 per share
Price ranges for individual trades within the weighted average sale prices
Key Terms
weighted average price, Stock Option (Right to Buy), derivative security, vesting, +1 more
5 terms
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions..."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Stock Option (Right to Buy) financial
""Stock Option (Right to Buy)" listed as the derivative security title for the option position"
derivative security financial
"Exercise or conversion of derivative security described for transaction code "M""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"shares subject to the option vested or shall vest in monthly installments thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
exercise or conversion financial
"transaction code description: Exercise or conversion of derivative security"
FAQ
What insider transactions did Aktis Oncology (AKTS) report for Akos Czibere?
Aktis Oncology’s Chief Medical Officer Akos Czibere exercised 50,000 stock options at $4.95 and sold 50,000 Common Shares in open-market transactions on July 8, 2026, fully offsetting the exercised shares.